ILOs

• the minimum pathology data a clinician should expect to use in order to make appropriate treatment decisions in breast cancer, including classical morphological data (tumour size, grade, excision status, lymph node involvement, and vascular invasion) and protein expression data including ER, PR and Her2 status; and how these data influence treatment decisions.
• comment on factors which may be detrimental to breast cancer data quality,
• understand how clinicians and pathologists can work together to ensure a high standard of care, and the role of external quality assurance.

• Here’s the list of people that need to be involved in the treatment of breast cancer!
• Sometimes, you have to ‘cast the net wider though’
• What are the benefits of this MDT?
• What does the MDT actually come together and discuss?
• What does a histology report tell us?

Patient Cases

• Case 1
• Case 2
• Case 3
• Case 4
• Case 5
• Case 6
• Case 7

The Changing Face of Breast Cancer

• Here’s how the survival rate is changing…